Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

MariTide, Amgen's candidate for obesity treatment, has emerged as a focal point for investors. Phase II topline results are expected in late 2024, with analysts anticipating data that could ...

MariTide, Amgen's candidate for obesity treatment, has emerged as a focal point for investors. Phase II topline results are expected in late 2024, with analysts anticipating data that could position ...

Heart disease remains the leading cause of death in the U.S.

Heart disease remains the number one killer worldwide, outstripping all other causes of death as key risk factors continue to ...

Highlights: According to the American Heart Association's 2025 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of ...

The current definition of obesity, as set by the World Health Organization ... This is impacted by a person’s race and ethnicity, their age, what foods they eat, and genetics plays a tremendous ...

Black people with obesity are less likely to get weight-loss surgery than others.Black people are just as likely to d ...

Defining obesity as a disease has been a sea change ... the wide variability in risk tied to BMI that doesn’t account for race and ethnicity. Criteria for waist circumference as a measure ...

SAN FRANCISCO ― Hanmi Pharmaceutical is poised to bring a new chapter to obesity treatment, a topic that has garnered significant attention at this year’s JP Morgan Healthcare Conference.

Metsera is, of course, not alone in the race to improve upon Novo Nordisk’s and Eli Lilly’s approved obesity treatments. Just last week, Verdiva Bio unveiled with $410 million and a clinical ...